Scaling Innovation in Genetics and Precision Medicine

INSEAD Knowledge· July 28, 2026

INSEAD Knowledge has released a publication titled 'Scaling Innovation in Genetics and Precision Medicine.' The title indicates a focus on the growth and implementation of genetic technologies within the healthcare industry. Understanding the scaling of such innovations is a key concern for the Genomics & Precision Medicine sector as it moves toward clinical integration. This publication highlights the ongoing efforts to transition genetic research into scalable medical solutions.

Read the full story at INSEAD Knowledge

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to INSEAD Knowledge.

More in Genomics & Precision Medicine

Scaling Genomics for Precision Medicine

The genomics sector is shifting its focus from foundational research to the clinical translation of genomic insights at scale. Next-generation microarray platforms are addressing historical bottlenecks by integrating complex workflows into automated systems, significantly reducing turnaround times and operational costs. This technological evolution is critical for the expansion of precision medicine, particularly in pharmacogenomics and large-scale population studies.

July 18, 2026

Illumina appoints Susan Martin to lead ANZ operations

Illumina has named Susan Martin as the new General Manager for its Australia and New Zealand (ANZ) operations, a move aimed at driving commercial growth and market expansion in a region increasingly focused on genomic medicine. Martin, who previously served as Managing Director for Johnson & Johnson MedTech ANZ, will oversee the company's efforts to integrate sequencing technologies into clinical and public health settings. This leadership transition highlights the growing importance of the ANZ market as healthcare systems there transition genomics from a research-focused tool to a routine component of patient care pathways.

July 13, 2026

Precision Medicine Market Projected to Reach $544 Billion by 2035 as Genomic Sequencing and AI Adoption Accelerate

The global precision medicine market is undergoing a significant transformation, with its valuation expected to grow from $118.69 billion in 2025 to $544.26 billion by 2035. This growth is driven by the increasing integration of genomic sequencing, artificial intelligence, and molecular diagnostics into standard clinical workflows to address rising rates of cancer and rare genetic disorders. As the sector shifts from generalized treatments to personalized care, major pharmaceutical and technology firms are intensifying their investments in targeted therapies and companion diagnostics to improve patient outcomes.

July 7, 2026

Molecular biology enzymes and kits market to hit $70.85B by 2035, driven by genomics and diagnostics growth

The global market for molecular biology enzymes, reagents, and kits is projected to reach $70.85 billion by 2035, growing at a compound annual growth rate of 9.68% from its 2025 valuation of $27.69 billion. This significant expansion is primarily fueled by the rising adoption of molecular diagnostics, genomics research, and precision medicine initiatives across the healthcare landscape. As pharmaceutical and biotechnology sectors increase their reliance on advanced genetic tools, the market is expected to see sustained demand for core technologies such as PCR and gene editing.

July 6, 2026